Avian Paramyxovirus 7

Overview, Taxonomy, and Nomenclature of Avian Paramyxovirus 7

Avian Paramyxovirus serotype 7 (APMV-7) represents one of the less extensively characterized members within the genus Avulavirus in the family Paramyxoviridae. Unlike its more notorious relative APMV-1 (Newcastle disease virus), APMV-7 is generally considered avirulent for chickens as evidenced by its long mean death time in embryonated eggs (exceeding 144 hours) and restricted replication in cell culture [1]. The prototype strain, dove/Tennessee/4/75, was sequenced completely and revealed a genome length of approximately 15,480 nucleotides, which adheres strictly to the “rule of six,” a hallmark of paramyxoviruses whereby the genome length is a multiple of six [1]. This structural requirement is of major biological significance, as it ensures optimal encapsidation of the viral RNA and efficient replication by the RNA-dependent RNA polymerase [1].

The APMV-7 genome is organized into six non-overlapping genes arranged sequentially in the order 3′-N-P/V/W-M-F-HN-L-5′. The nucleoprotein (N) is encoded at the 3′ end and plays a central role in encapsidating the viral RNA [1], while the phosphoprotein (P) gene is notable for containing a conserved RNA editing site (with the consensus 3′-UUUUUCCC-5′ sequence) that is involved in the production of accessory proteins such as V and W [1]. These accessory proteins have been implicated in modulating host immune responses in other paramyxoviruses, although their precise role in APMV-7 remains to be fully elucidated [1]. Following the P gene is the matrix (M) protein gene, which is critical for virus particle assembly [1]. The fusion (F) protein, which harbors a cleavage site with a single basic amino acid (notably the conserved motif 101TLPSSR↓F107), is a key determinant of virulence; in the case of APMV-7, this monobasic cleavage site is correlated with its avirulent phenotype and restricted proteolytic activation in host tissues [1]. The hemagglutinin-neuraminidase (HN) protein, encoded immediately after F, plays dual roles in virus attachment to sialic acid receptors and in facilitating the release of newly formed virions [1]. The genome concludes with the large (L) polymerase gene, which is responsible for the transcription and replication of the viral genome [1]. In addition, the 3′ leader (55 nucleotides) and the 5′ trailer (127 nucleotides) regions possess highly conserved sequences that feature complementary stretches at their extreme ends, ensuring proper encapsidation and regulation of transcription by the viral polymerase [1].

Taxonomy

In the context of viral taxonomy, APMV-7 is classified within the genus Avulavirus, a group that encompasses up to 22 different serotypes isolated from a wide range of avian hosts [2]. Taxonomic distinctions in this group are primarily based on differences in complete genome sequences, antigenic properties assessed via hemagglutination inhibition assays, and genetic signatures such as the gene order and intergenic regulatory sequences. Phylogenetic analyses have demonstrated that APMV-7 clusters more closely with certain serotypes – in particular APMV-2, APMV-6, and APMV-8 – than with other members such as APMV-1, APMV-3, APMV-4, or APMV-9 [1]. This evolutionary relationship implies that despite the varied pathogenic outcomes observed in different serotypes, these viruses share a common evolutionary lineage with conserved genomic architecture but diverge in specific motifs that influence host range, tissue tropism, and virulence.

Given its relatively restricted host range in vitro and the epidemiological data suggesting low virulence in poultry, APMV-7 holds an important position within avian virology. It contrasts with the highly pathogenic features of APMV-1 yet is still subject to rigorous attention by both veterinary researchers and international animal health organizations such as the World Organisation for Animal Health (WOAH) and the World Health Organization (WHO). These organizations, along with the Centers for Disease Control and Prevention (CDC) and the Food and Agriculture Organization (FAO), emphasize the importance of characterizing even less pathogenic avian viruses, as genetic changes or reassortment events may alter their virulence or host range, contributing to potential zoonotic or economically significant outbreaks.

Nomenclature

The nomenclature of avian paramyxoviruses follows a systematic approach based on serological differentiation, genomic characteristics, and the geographical or host origin of the isolate. In the specific case of APMV-7, the designation “7” indicates its serological distinctiveness from other APMV serotypes, a classification supported by both antigenic tests and nucleotide sequence divergences [1]. The prototype strain, dove/Tennessee/4/75, incorporates both the host species (dove) and geographic origin (Tennessee) into its designation, which is a common practice in the naming conventions for avian paramyxoviruses [1]. Such a nomenclature strategy aids in tracing the epidemiological and evolutionary history of each serotype and facilitates standardized communication among researchers worldwide [1].

The classification and naming of APMV-7 are grounded in extensive comparative analyses of viral genomic sequences. The unique genetic features of the APMV-7 genome, including the lengths of the untranslated regions, the configuration of the gene-start and gene-end signals, and the presence of conserved motifs within the open reading frames, solidify its position as a distinct serotype within the Avulavirus genus [1]. The taxonomic framework established for APMV-7 is not only supported by molecular data but is also in line with the serological differentiation methodologies that have been historically employed. The continued refinement of these taxonomic criteria is critical as next-generation sequencing technologies reveal further intragenotypic diversity and potential recombination events, as observed in other avian paramyxovirus serotypes [1].

Moreover, the nomenclatural practices for APMVs are of considerable importance to regulatory agencies and disease control bodies. Accurate identification and classification facilitate prompt response measures in the event of an outbreak, ensuring that both public health and economic interests are safeguarded. APMV-7, while currently recognized as avirulent, is monitored under surveillance programs implemented by agencies including the CDC and FAO, which mandate standardized reporting and diagnostic testing protocols to prevent any unforeseen shifts in pathogenicity that might impact domestic poultry and wild bird populations.

Through a detailed understanding of the overview, taxonomy, and nomenclature of APMV-7, researchers are better equipped to assess its evolutionary dynamics, host interactions, and potential future implications. This deep molecular and serological characterization not only enhances our comprehension of avian paramyxovirus diversity but also informs broader strategies for surveillance and disease management in the global context.

Molecular Structure and Genomic Organization of Avian Paramyxovirus 7

Avian paramyxovirus serotype 7 (APMV-7) is characterized by a non-segmented, negative-sense single-stranded RNA genome that exemplifies the conserved structural features of the Paramyxoviridae family. Detailed molecular analysis of the APMV-7 genome, as reported by Xiao et al. [1], reveals a genome length of approximately 15,480 nucleotides that adheres strictly to the “rule of six.” This rule, requiring the genome length to be an even multiple of six nucleotides, ensures optimal encapsidation and replication fidelity by the nucleocapsid protein. The precise arrangement of the genome is central to the virus’s ability to replicate and modulate host responses, a aspect that bears significant implications when considering both its pathogenicity and potential application in vaccine vector technology.

Genomic Architecture and Gene Order

The genomic organization of APMV-7 is laid out in an archetypal manner that includes six non-overlapping genes arranged sequentially as 3′-N-P/V/W-M-F-HN-L-5′. The first gene encodes the nucleocapsid (N) protein, which is responsible for encapsidating the RNA genome and forming a helical ribonucleoprotein complex. Following the N gene, the phosphoprotein (P) gene is expressed and subsequently edited at a highly conserved RNA editing site (3′-UUUUUCCC-5′). This site permits polymerase slippage resulting in the generation of additional proteins, namely, the V and W proteins, which play roles in antagonizing host interferon responses and fine-tuning virus–host interaction dynamics. The strategic placement and expression of these accessory proteins underscore the virus's capacity to evade immune responses and adapt to diverse host environments.

The matrix (M) protein gene, located immediately downstream of the P/V/W gene, encodes a protein that is pivotal for viral assembly and budding. The M protein provides the bridge between the ribonucleoprotein complex and the viral envelope, coordinating the budding process at the host cell membrane, a critical step for the formation of infectious viral particles.

The fusion (F) protein gene, central to the virus’s ability to mediate entry into host cells, encodes a glycoprotein that undergoes proteolytic activation. Notably, in APMV-7 the F protein cleavage site is composed of a single basic amino acid. This sequence feature is commonly associated with viruses that are avirulent or display a restricted host range because the cleavage process is less efficient and does not require exogenous proteases for activation during in vitro replication. Activation of the F protein is a prerequisite for membrane fusion, and its molecular configuration in APMV-7 suggests a regulated fusion process that might contribute to its naturally low virulence in poultry populations.

Downstream from the F gene, the hemagglutinin-neuraminidase (HN) protein gene encodes a multifunctional glycoprotein responsible for receptor binding and for promoting viral egress by cleaving sialic acid residues from host cell surfaces. The dual functionality of the HN protein is typical of avulaviruses and supports both entry into host cells and release from infected cells. In APMV-7, the HN protein has been shown to maintain a sequence that facilitates these dual roles, thereby optimizing viral spread within the host.

The final gene in the genome is the large polymerase (L) gene, coding for the RNA-dependent RNA polymerase. The L protein is integral to both transcription and replication of the viral RNA genome. Its large size and multifunctional enzymatic activities, which include RNA synthesis and capping, underscore its pivotal role in directing the lifecycle of the virus. The conservation observed in the L gene among various paramyxoviruses suggests that, despite variations in host range and pathogenic potential, the molecular machinery responsible for RNA synthesis remains remarkably conserved.

Regulatory Elements and Intergenic Sequences

Flanking the coding regions of the APMV-7 genome are the 3′ leader and the 5′ trailer sequences, which are 55 and 127 nucleotides long, respectively. These nucleotide sequences not only serve as essential promoters for viral RNA synthesis but also exhibit a high degree of complementarity at their first 12 nucleotides. This complementarity is thought to facilitate the encapsidation process and ensure the fidelity of transcription, thereby impacting the virus’s replicative efficiency.

Each gene within the genome is demarcated by highly conserved gene-start (GS) and gene-end (GE) transcription signals. These regulatory motifs are critical for the orderly transcription of the viral genome and for ensuring that each gene is expressed in a sequential and gradient-like fashion, a phenomenon well-documented in members of the Paramyxoviridae family. Intervening these genes are intergenic sequences (IGS) whose lengths vary from 11 to 70 nucleotides. These IGS regions contribute to the regulation of transcription termination and reinitiation, thus playing a subtle yet essential role in modulating the levels of viral proteins produced during infection.

Evolutionary and Phylogenetic Context

Phylogenetic analyses based on the complete genomic sequence of APMV-7 indicate that this serotype shares a closer relationship with other avian paramyxovirus serotypes such as APMV-2, -6, and -8, rather than with the well-studied APMV-1 (Newcastle disease virus) [1]. This evolutionary divergence is not merely a taxonomic curiosity but has practical implications for understanding transmission dynamics and virulence. Regulatory bodies such as the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH) continually emphasize the importance of molecular surveillance in non-zoonotic yet economically impactful viruses like those infecting avian populations. Such surveillance is crucial for regions where cross-species transmission could have severe economic ramifications for the poultry industry.

Furthermore, the detailed genomic organization of APMV-7, including the modular nature of its gene segments and the presence of RNA editing mechanisms, underscores the virus’s evolutionary adaptability. The precision of transcriptional control via GS and GE signals, combined with the fine-tuning afforded by intergenic regions and leader/trailer sequences, paints the picture of a finely balanced virus that is both efficient in replication and calibrated in pathogenicity. This molecular blueprint, while structurally reminiscent of other members of the Paramyxoviridae family, is uniquely tailored to the ecological niche occupied by APMV-7.

In summary, the molecular structure and genomic organization of APMV-7 embodies a sophisticated array of genetic elements that work in concert to ensure replication, immune modulation, and host specificity. Each gene, in its sequential arrangement from the N gene to the L gene, plays a distinct role that contributes to the overall viral phenotype. This intricate organization, supported by a network of regulatory signals and RNA editing phenomena, reflects an evolutionary strategy that balances replication efficiency with low pathogenic potential, a feature that has important implications for both disease ecology and the development of novel vaccine technologies.

Molecular Pathogenesis and Host-Cell Interactions of Avian Paramyxovirus 7

Avian Paramyxovirus 7 (APMV-7) is characterized by a genome organization that follows the canonical non-segmented, negative-strand RNA virus architecture, with a genome length of 15,480 nucleotides arranged as 3′-N-P/V/W-M-F-HN-L-5′ [1]. This genomic layout is fundamental to its replication strategy and underpins the molecular pathogenesis observed in host cells. The leader and trailer sequences, which are 55 and 127 nucleotides in length respectively, are highly conserved elements that flank the coding region [1]. These regulatory sequences, together with conserved gene-start (GS) and gene-end (GE) signals, facilitate a sequential transcription process by the viral RNA-dependent RNA polymerase (L protein) [1]. The resulting gradient of mRNA accumulation from the 3′-end to the 5′-end is pivotal in ensuring proper stoichiometry of structural and accessory proteins that manipulate host cellular machinery during infection [1].

Genome Organization and Viral Proteins

Central to the molecular interactions with host cells are the viral proteins encoded by the genome. The nucleoprotein (N) encapsidates the viral RNA, forming ribonucleoprotein complexes necessary for both transcription and replication. The phosphoprotein (P) gene, notable for its conserved RNA editing site, produces not only the P protein itself but also accessory proteins such as V and W through a process of co-transcriptional editing [1]. These accessory proteins are implicated in antagonizing the host’s innate immune responses, a common theme among paramyxoviruses where inhibition of interferon-stimulated pathways allows for evasion of antiviral defense mechanisms [1].

The matrix (M) protein plays a crucial role in virus particle assembly and budding. Although its direct interaction with host cell pathways is less well documented for APMV-7 specifically, insights from the broader Paramyxoviridae family suggest that M protein can interface with cellular trafficking machinery to mediate virion egress.

The structural glycoproteins, Fusion (F) protein and Hemagglutinin-Neuraminidase (HN) protein, are central to host-cell interactions. The F protein, responsible for mediating fusion between the viral envelope and the host cell membrane, features a cleavage activation site sequence (101TLPSSR↓F107) that contains only a single basic residue [1]. Despite this ostensibly low-virulence signature, APMV-7 demonstrates the ability to replicate in vitro without the need for exogenously provided proteases. This observation implies that host cell proteases are sufficiently robust or specifically targeted to process the F protein under natural infection conditions, thereby enabling effective viral entry even in the absence of a multibasic cleavage motif [1]. In parallel, the HN glycoprotein governs the initial attachment of the virus to the sialic acid-containing receptors on the surface of susceptible cells. Its role is not only in mediating cell entry but also in balancing the fusion activity of the F protein, ensuring that membrane fusion occurs optimally to facilitate viral replication without triggering excessive cytopathic effects.

Fusion Protein Activation and Restricted Host Cell Tropism

A defining feature of APMV-7’s molecular pathogenesis is its peculiar profile of host cell tropism. The fusion protein’s cleavage activation, despite its relatively monobasic configuration, seems to be efficiently executed by host proteases in select cellular environments [1]. This finely tuned activation process is fundamental to the virus’s ability to infect a limited number of cell lines, as evidenced by its restricted replication in vitro [1]. The dependence on host-specific proteolytic activity may explain why APMV-7 exhibits a narrow cell-type specificity, thereby contributing to its overall avirulent phenotype in chickens. Such restricted cell tropism is a double-edged sword, it limits widespread pathogenicity in a potential poultry host, yet it ensures that the virus can persist in natural reservoirs by establishing low-level, subclinical infections.

The interplay between the F and HN proteins is a critical determinant of cell entry efficiency. Structural variations within the HN protein in APMV-7 share evolutionary links with serotypes 2, 6, and 8 [1]. These evolutionary relationships underscore the functional conservation of receptor engagement mechanisms across related avian paramyxoviruses and hint at a common strategy wherein subtle differences in glycoprotein conformation dictate the receptor specificity and host cell compatibility. This specificity is not only responsible for the initial attachment and fusion process but also contributes to modulating subsequent immune responses by influencing the kinetics of viral entry and the presentation of viral antigens to host immune surveillance systems.

Innate Immune Modulation and Intracellular Replication

Once entry has been achieved, APMV-7 capitalizes on its intracellular machinery to subvert host defense mechanisms. The production of accessory proteins through RNA editing in the P gene is presumed to play a significant role in interfering with the interferon response, a hypothesis supported by studies on analogous proteins in other paramyxoviruses [1]. By inhibiting key signaling intermediates such as STAT1, these proteins can dampen antiviral cytokine responses, thereby creating a more permissive environment for replication [1]. Although detailed studies on the specific interactions between APMV-7 accessory proteins and host cellular factors are pending, the conservation of these molecular motifs suggests a similar immune evasion strategy.

Furthermore, the L protein, functioning as the viral RNA polymerase, engages with host cell factors that are essential for nucleocapsid assembly and mRNA synthesis. The precision of this molecular machinery is crucial, as errors in viral replication can trigger host cell stress responses, including apoptosis. By maintaining a controlled rate of replication, APMV-7 appears to limit the extent of acute cytopathic damage, thereby facilitating a balanced interaction with the host cell that supports persistent viral replication without overt clinical disease.

Implications for Surveillance and Zoonotic Considerations

While APMV-7 has been largely characterized as avirulent in chickens, with a mean death time in embryonated eggs exceeding 144 hours [1], its molecular features underscore the potential for subtle host adaptations. The efficient yet restricted replication in specific cell types, combined with molecular mechanisms for innate immune evasion, suggests that even avirulent strains could serve as reservoirs for genetic recombination or mutation events. Such events might alter host range or virulence profiles, a concern that is particularly relevant to international surveillance efforts coordinated by agencies such as the CDC, WHO, and WOAH. Although APMV-7 is not currently recognized as a major zoonotic threat, its molecular pathogenesis offers critical insights into the evolutionary dynamics that govern host-virus interactions within the broader context of avian paramyxoviruses [1].

In summary, the molecular pathogenesis and host-cell interactions of APMV-7 are orchestrated by a combination of conserved genomic organization, finely balanced fusion activation mechanisms, and strategic immune evasion tactics. These molecular determinants not only define its restricted host range and avirulent behavior in poultry but also provide a window into the evolutionary pressures that shape the interactions of avian paramyxoviruses with their hosts.

Epidemiology, Transmission Dynamics, and Host Range of Avian Paramyxovirus 7

Avian paramyxovirus serotype 7 (APMV-7) has been characterized as an avian virus whose complete genome was determined to be 15,480 nucleotides in length, following the “rule of six” essential for members of the Paramyxoviridae [1]. Unlike the highly pathogenic APMV-1 strains that have garnered extensive global attention due to their economic impact on poultry production and sporadic zoonotic potential acknowledged by agencies such as the CDC and WOAH, APMV-7 has been isolated under circumstances indicating a markedly different biological behavior. Its genomic architecture, comprising non-overlapping genes in the order 3′-N-P/V/W-M-F-HN-L-5′, underpins a unique set of replicative and transmission attributes that influence its epidemiology and host interactions.

Epidemiological Insights

Research into the epidemiology of APMV-7 remains limited when compared to extensively studied serotypes like APMV-1. The prototype strain, originally isolated from a dove in Tennessee in 1975, exhibits characteristics that have important implications for its detection and surveillance in wild bird populations [1]. The mean death time in embryonated chicken eggs for APMV-7 exceeds 144 hours, indicating an avirulent nature in chickens; this is a stark contrast to the virulent strains of NDV (APMV-1) that are notorious for causing high mortality in poultry. The absence of overt clinical disease in domestic avian species suggests that transmissions may occur silently within wild bird reservoirs, which historically have served as a critical viral reservoir for various avian pathogens.

Given the expertise provided by global animal health authorities such as the FAO and WOAH regarding emerging avian pathogens, it is essential to note that surveillance programs routinely target wild bird populations in migratory flyways. Although specific surveillance data on APMV-7 are limited, the paradigms established by studies on other APMVs [3, 4] imply that viruses with subtle or asymptomatic presentations, like APMV-7, could be circulating undetected amongst wild avifauna. Such silent circulation in reservoir species poses significant challenges for early detection and underscores the need for enhanced molecular diagnostics in routine wildlife monitoring programs.

Transmission Dynamics and Biological Mechanisms

Transmission of APMV-7 appears to be governed by factors that are both intrinsic to the virus and extrinsic, involving host behavior and environmental conditions. The virus’s replication in only a handful of established cell lines, as demonstrated in vitro, hints at a narrow tissue or host cell tropism [1]. This restricted replication likely reflects adaptations to specific host receptors, suggesting that APMV-7 might require precise cellular factors that are predominantly present in certain avian species. In vivo experimental inoculations, although sparse for APMV-7 in published literature, indicate a pattern similar to other avirulent avian paramyxoviruses where the virus does not cause systemic infections; rather, replication is limited to particular compartments of the host that facilitate natural transmission cycles.

Biologically, the presence of a single basic residue at the fusion (F) protein cleavage site in APMV-7 indicates a limited capacity for proteolytic activation by ubiquitous host proteases. This molecular determinant of virulence not only accounts for the avirulent phenotype in chickens but also suggests a lower potential for systemic spread, which is commonly associated with the enhanced pathogenicity seen in viruses possessing multibasic cleavage motifs [1]. In this context, the molecular design of the F protein serves as a mechanistic barrier that restricts the virus’s ability to move beyond localized infection sites, thereby shaping its transmission dynamics. Comparable studies on the molecular underpinnings of other APMVs [5, 6] have highlighted that cleavage site composition is a central factor in defining tissue tropism and virulence, reinforcing the need to understand APMV-7’s proteolytic activation in natural hosts.

Host Range Considerations

APMV-7’s host range appears to be limited compared to some of its counterparts. The original isolation from a dove indicates that this serotype may be more adapted to a select set of wild bird species, particularly those that are not typically implicated in mass poultry outbreaks. Phylogenetic analyses placing APMV-7 in closer relation to APMV-2, -6, and -8 [1] imply that its evolutionary trajectory has favored a niche compartment among birds that might not interface directly with commercial poultry operations. Such a host restriction is beneficial from an epidemiological standpoint, as outbreaks in domestic species, which are more intensively monitored by organizations such as the CDC, WHO, and WOAH, tend to attract rapid mitigation responses.

Despite its limited host range in domesticated birds, the transmission dynamics within wild avifauna cannot be overlooked. Migratory patterns, particularly in waterfowl and certain perching birds, are known to facilitate the geographic spread of diverse APMVs [3, 7]. Although APMV-7 has not been reported to establish persistent infections in poultry, the potential for interspecies transmission among wild birds emphasizes the importance of continued surveillance. The restricted host tropism of APMV-7 indicates that it might have co-evolved with particular bird species, likely benefitting from ecological niches with lower immune pressures and minimal interference from vaccination programs, a scenario extensively documented in the epidemiology of other paramyxoviruses [4, 8].

The selective pressure exerted by natural host immunity and potential recombination events, although more frequently described in APMV-1 [9, 10], could also shape the future evolutionary dynamics of APMV-7. Indeed, restricted host range viruses are often subject to periodic bottlenecks that can lead to genetic drift or even punctuated evolutionary shifts, resulting in emergent strains with altered host interaction properties. Recognizing these mechanisms is crucial for risk assessments conducted by global animal health authorities, especially given the complex interplay between wild and domestic reservoirs which may, under certain circumstances, facilitate genetic exchange.

Integration with Global Surveillance Paradigms

While current knowledge suggests that APMV-7 is primarily an avirulent virus with a narrow host range, its characterization contributes to the broader understanding of avian paramyxovirus diversity. In surveillance programs advocated by the CDC and FAO, molecular surveillance and genomic sequencing are critical tools in monitoring the emergence of potential new variants, even from seemingly benign viruses [11, 12]. Although APMV-7 does not presently pose a direct economic threat to domestic poultry, its evolution and transmission among wild birds could have unforeseen implications, particularly if environmental or anthropogenic factors trigger host range expansion or increase viral fitness.

The integration of detailed genomic insights, such as those provided by next-generation sequencing studies [1], into epidemiological frameworks helps refine risk models for avian viral diseases. Such models are indispensable when advising policy and formulating response strategies for avian diseases with pandemic potential as outlined by the WHO. Therefore, an enhanced focus on the collection of epidemiological data, coupled with molecular surveillance in wild avian populations, is warranted to ensure that emerging strains of APMV-7, however rare, are identified and their transmission routes elucidated early in the course of potential outbreaks.

Overall, the epidemiology and transmission dynamics of APMV-7 highlight a virus that, while currently limited in its host range and pathogenic impact, represents an integral component of the diverse avian paramyxovirus family. Its evolution, maintained largely in wild bird populations with minimal overt clinical disease, underscores the need for comprehensive surveillance and detailed molecular characterization to pre-empt any shifts in host range or pathogenic properties that could have broader implications for animal health and, potentially, zoonotic transmission in the future.

Diagnostics and Laboratory Detection Strategies for Avian Paramyxovirus 7

The diagnostic approach for avian paramyxovirus serotype 7 (APMV-7) requires a multi-tiered laboratory strategy combining classical virological methods with advanced molecular techniques. The primary goal is to accurately detect, characterize, and differentiate APMV-7 from other avian paramyxoviruses to support surveillance efforts, not only in commercial poultry but also in wild bird reservoirs that may contribute to viral dissemination.

Virus Isolation and Culture Considerations

Traditional virus isolation remains a cornerstone methodology in detecting avian paramyxoviruses. For APMV-7, isolation in embryonated chicken eggs has been adopted as a standard practice due to the virus’s restricted growth in conventional cell lines. The cultivation process involves inoculating clinical specimens such as tracheal or cloacal swabs into fertile chicken eggs under controlled conditions. Optimization of culture conditions, including temperature and pH, is essential because APMV-7 displays a lower replication efficiency and a narrower host cell tropism compared to more widely studied serotypes like APMV-1. Once isolated, subsequent passages of the virus can lead to an increase in viral titers, which is critically important for downstream diagnostic evaluation and genomic characterization [1].

Molecular Diagnostic Approaches

Modern diagnostics often begin with the use of molecular methods, especially real-time reverse transcription PCR (rRT-PCR), which offers high sensitivity and specificity. rRT-PCR assays for paramyxoviruses typically target conserved regions of the genome such as the fusion (F) gene, which, in the case of APMV-7, contains a distinct cleavage site (with a single basic amino acid residue, TLPSSR↓F) that also serves as an important virulence marker [1]. The design of primers and probes that specifically anneal to conserved sequences in the leader or trailer regions, both of which are short, highly conserved sequences that obey the “rule of six”, can enhance the diagnostic yield and minimize the risk of cross-reactivity with other serotypes. Studies on avian paramyxoviruses have shown that optimization of these sequences is critical for detecting low viral loads in clinical samples, thereby ensuring early and accurate detection.

An additional molecular strategy involves conventional RT-PCR followed by sequencing of amplified gene segments. This is particularly useful in confirming the identity of APMV-7 isolates and distinguishing them from closely related avian paramyxovirus serotypes. PCR-based assays can also be coupled with high-resolution melting curve analysis to detect subtle differences in nucleotide composition, aiding in subtyping and in monitoring genetic drift within viral populations. Given that APMV-7 has a genome 15,480 nucleotides in length with a defined gene order (3′-N-P/V/W-M-F-HN-L-5′), complete or partial genome sequencing serves as an invaluable tool for elucidating key genomic determinants of virulence and host-range specificity [1].

Serological Assays and Antigen Detection

Complementary to nucleic acid–based detection, serological assays play a pivotal role in the epidemiological investigation of APMV-7. Hemagglutination (HA) assays are routinely employed because many avian paramyxoviruses, including APMV-7, possess the hemagglutinin-neuraminidase (HN) protein on their surface. However, caution is warranted: the sensitivity of HA tests for APMV-7 can be lower than that observed for other serotypes due to its unique antigenic properties and sometimes, its low titers in field samples. Hemagglutination inhibition (HI) assays further enhance the specificity by using serum antibodies raised against known viral antigenic sites. These assays have proven effective in distinguishing between vaccine-induced antibodies and those generated during natural infection in other avian paramyxoviruses [13, 14].

Furthermore, the development of enzyme-linked immunosorbent assays (ELISAs) targeting recombinant proteins, such as the nucleocapsid (NP) and phosphoprotein (P), is being explored. These assays utilize bacterially expressed recombinant antigens that, when used in early diagnostic contexts, help to differentiate between various APMV serotypes. Although much of the work with these assays has been conducted on APMV-1 and related serotypes [15], the principles are directly applicable to APMV-7; careful antigen design can alleviate issues related to cross-reactivity and improve assay specificity.

Genome Sequencing and Phylogenetic Analysis

Genomic sequencing has become indispensable in modern diagnostics. For APMV-7, full-genome sequencing not only confirms the presence of the virus but also provides detailed insight into its evolutionary lineage and potential recombination events. Next-generation sequencing (NGS) platforms have been instrumental in characterizing the complete genome of APMV-7. The availability of complete genome data, as demonstrated in recent work, facilitates the detection of genetic markers that determine host specificity and replication requirements, for instance, understanding the relevance of the conserved gene-start (GS) and gene-end (GE) signals enhances the design of molecular probes [1].

Phylogenetic analysis further aids in situating APMV-7 within the broader context of avian paramyxoviruses. Detailed analyses of the viral genome help delineate its relationship with other serotypes, particularly APMV-2, -6, and -8, which share higher sequence homology with APMV-7 than with APMV-1, -3, -4, or -9. This differentiation is critical because accurate serotype identification can influence both outbreak management and decisions regarding control strategies in vaccination programs. Regulatory bodies like the World Organisation for Animal Health (WOAH), the Food and Agriculture Organization (FAO), as well as guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) underscore the importance of integrating genomic surveillance into diagnostic workflows for economically important avian pathogens.

Differentiation Strategies and Assay Optimization

One of the significant challenges in the laboratory detection of APMV-7 is differentiating it from other circulating avian paramyxoviruses, especially in regions where multiple serotypes co-circulate. The genomic sequence of APMV-7 provides important clues for assay design. For example, the specific configuration of its phosphoprotein gene, which includes a conserved RNA editing site (key for generating additional proteins such as V and W), offers potential targets for strain differentiation [1]. Assays must be meticulously validated to ensure that primers designed for APMV-7 do not cross-react with similar sequences present in other serotypes.

In some instances, multiplex RT-PCR assays have been proposed that can simultaneously detect several avian paramyxoviruses in a single reaction. This approach, while logistically efficient, demands a high level of assay specificity. The use of probe-based multiplex assays with fluorophore-labelled oligonucleotides can help achieve this goal by permitting real-time detection with minimal interference among targets.

Integration of Advanced Diagnostic Platforms

The integration of advanced diagnostic platforms, including NGS and digital droplet PCR, represents the frontier of APMV-7 detection. These cutting-edge approaches can overcome limitations imposed by low viral loads and genetic diversity within field isolates. For example, digital droplet PCR offers the potential to quantify viral genomes with exquisite sensitivity, an advantage that may prove crucial when managing low-level or subclinical infections. Although such platforms are still emerging in routine veterinary diagnostics, their implementation aligns with the recommendations of international health organizations for monitoring high-priority pathogens, as evidenced in the guidelines put forth by the CDC, WHO, and WOAH.

Collectively, these diagnostic and laboratory detection strategies form a comprehensive framework for the identification and characterization of APMV-7. The multi-dimensional approach, ranging from virus isolation and culture to sophisticated molecular and serological assays, ensures that laboratories can reliably detect and monitor this pathogen in both clinical and field settings.

Immunogenicity of Avian Paramyxovirus 7

Avian Paramyxovirus 7 (APMV-7) exhibits a unique immunogenic profile that has garnered interest for potential applications in avian vaccine development and control measures within the poultry industry. At the molecular level, the complete genome sequence of APMV-7, as determined for the prototype strain from Tennessee, reveals several features integral to its immunogenicity. The virus, which adheres to the “rule of six,” possesses six non-overlapping genes arranged in the order 3′-N-P/V/W-M-F-HN-L-5′ [1]. This genomic organization, along with a conserved leader and trailer sequence, plays a fundamental role in viral replication and the subsequent induction of host immune responses. Notably, the fusion (F) protein of APMV-7 contains a single basic amino acid at the cleavage site, indicating that the virus does not require exogenous protease for replication. This distinct characteristic not only contributes to its low pathogenic profile in chickens but also affects the way host immune systems perceive and respond to the viral antigens. The absence of a multibasic cleavage site, typically associated with enhanced virulence and widespread systemic infection, suggests that APMV-7 elicits sharp but contained innate and adaptive immune responses, which could be advantageous when considering virus-derived vaccine vectors. These observations align with the immunogenicity profiles seen in other avian paramyxoviruses that are being evaluated for vaccine potential, as reported by various investigators [16, 17].

Vaccine Development Utilizing APMV-7

Vaccine development strategies over the past decades have increasingly focused on attenuated viral vectors that can stimulate robust mucosal, humoral, and cellular immunity. In this context, APMV-7 has emerged as a promising candidate due to its intrinsic low virulence in chickens and its restricted host range [1]. The virus’s replication kinetics and inability to propagate efficiently in established cell lines suggest that it can be safely manipulated through reverse genetics to express foreign antigenic proteins. Recombinant APMV-based vaccine vectors have been successfully engineered in other serotypes, such as APMV-3 and even APMV-1 (NDV) [18-20]. Although much of the work in developing such vaccine candidates has concentrated on APMV-1 and related serotypes due to their economic importance as causes of Newcastle disease, the biological properties of APMV-7, including its distinct antigenic surface glycoproteins like hemagglutinin-neuraminidase (HN) and fusion (F) proteins, provide alternative immunostimulatory platforms that could be optimized for vaccine applications in poultry populations.

Recent work with APMV serotypes evaluated in various animal models, including mice and hamsters, has demonstrated that members of the Avulavirus genus elicit strong immune responses without causing severe clinical disease [18, 19]. With APMV-7 being avirulent for chickens, the recombinant engineering of this virus to express target antigens from economically critical or zoonotic avian pathogens remains a rational strategy. A vaccine vector based on APMV-7 could potentially stimulate high levels of virus-specific antibodies and T-cell responses, particularly against the HN and F proteins, which serve as major neutralization determinants. In experimental settings, the level of immunogenicity derived from viral vectors is greatly influenced by both the insertion site of the foreign gene as well as the stability and expression kinetics of the recombinant protein; these issues have been extensively characterized in serotypes such as APMV-3 [20, 21]. Drawing parallels from these studies, engineers can design APMV-7-based vectors by selecting gene junctions that promise high-level expression of the inserted antigen while not interfering with the native transcriptional gradient inherent to the viral genome.

Furthermore, the innate immune response elicited by APMV vectors is a key component of vaccine efficacy. Although APMV-7 induces only limited replication in established cell systems, the use of live recombinant vectors can promote local mucosal immunity in the respiratory tract, a critical factor for pathogens transmitted via respiratory routes. Given that global organizations such as the CDC, WHO, and WOAH emphasize the importance of effective immunization strategies against both zoonotic and economically significant avian pathogens, the exploration of APMV-7 as a vaccine vector offers significant promise. By leveraging modern molecular techniques, reverse genetics systems can be developed for APMV-7, enabling the production of recombinant viruses that afford safe, immunogenic, and stable vaccine candidates that might complement or even surpass current NDV-based vaccines.

Control Measures in the Context of Vaccine Strategies

A critical element in the integrated management of avian viral diseases involves not only the development of efficacious vaccines but also the implementation of robust control measures. The low virulence and restricted host range of APMV-7 in chickens, as demonstrated by its genome characteristics and in vivo behavior [1], support the potential for using either live-attenuated or vector-based vaccine approaches with minimal risk of inadvertent pathogenicity or unwanted virus release into the environment. Control measures for avian paramyxoviruses typically encompass a combination of rigorous surveillance, biosecurity advancements, and vaccination protocols that are in line with guidelines established by authoritative agencies such as the CDC, WHO, and the WOAH.

In the context of vaccination programs, it is imperative to monitor both the immune status of the birds via seroconversion studies and the spread of vaccine strains in the field. As demonstrated in surveillance studies of related APMV serotypes, serological assays, often based on enzyme-linked immunosorbent assays and hemagglutination inhibition tests, are valuable in discriminating between vaccinated and infected birds [17, 22]. The development of DIVA (Differentiating Infected from Vaccinated Animals) strategies is particularly pertinent for economically critical pathogens. Given that some recombinant constructs based on other APMV serotypes have already employed such strategies [15], similar approaches could be adapted for APMV-7 to further enhance control measures. The implementation of DIVA-compatible vaccines would allow regulatory bodies to perform sero-surveillance more effectively and to rapidly identify and isolate field strains in cases of outbreak.

Control measures also extend to the application of molecular diagnostic techniques, including real-time reverse transcription PCR (rRT-PCR) and genome sequencing to monitor virus circulation among both domestic and wild bird populations [23]. Frequent genomic surveillance, as recommended by FAO guidelines, is crucial to identify potential recombination events or antigenic drift that might compromise vaccine efficacy. The antigenic stability observed in low pathogenic strains like APMV-7 makes them attractive candidates in the long term; however, continued surveillance is needed to ensure that vaccine strains remain antigenically similar to circulating field strains.

In addition, the limited host range of APMV-7 offers inherent advantages in geographical areas with mixed-species poultry farming, where the risk of interspecies transmission can complicate control measures. Enhanced biosecurity protocols, as outlined by international standards from the WOAH and CDC, become more manageable when vaccine vectors demonstrate high specificity and safety profiles in target species. Field implementation strategies for vaccines based on APMV-7 would need to integrate these biosecurity measures with vaccination campaigns, particularly in regions experiencing recurrent outbreaks of avian diseases.

Overall, the combination of innovative vaccine development approaches, with special focus on recombinant APMV-7 vectors, and comprehensive control measures provides a robust framework for managing avian viral diseases. The intrinsic immunogenic properties of APMV-7, coupled with advanced molecular engineering techniques and stringent surveillance protocols, collectively contribute to a more controlled, effective, and sustainable approach toward mitigating the impact of avian paramyxoviruses on global poultry industries.

Evolution, Genetic Diversity, and Adaptive Mechanisms of Avian Paramyxovirus 7

Avian Paramyxovirus 7 (APMV-7) represents one of the less frequently encountered serotypes within the avulavirus genus, yet its unique evolutionary trajectory provides critical insights into the genetic plasticity and adaptive strategies employed by avian paramyxoviruses. Detailed genomic analysis of the prototype strain, dove/Tennessee/4/75, has outlined a genome spanning 15,480 nucleotides that adheres to the “rule of six” – a characteristic feature of many negative-sense single-stranded RNA viruses within the Paramyxoviridae family [1]. The genomic organization follows the canonical gene order of 3′-N-P/V/W-M-F-HN-L-5′, underscoring a conserved architecture observed across diverse serotypes, yet with serotype-specific adaptations that underlie its evolutionary success.

Genomic Architecture and Evolutionary Relationships

The complete genome sequence of APMV-7 reveals several molecular hallmarks that contribute to its evolutionary dynamics. Notably, the 3′ leader and 5′ trailer regions, which at 55 and 127 nucleotides respectively, display a conserved complementarity in their first 12 nucleotides. This conservation is pivotal for the encapsidation and replication of the viral RNA by its polymerase complex, ensuring fidelity during genome replication and transcription [1]. Additionally, the presence of highly conserved gene-start (GS) and gene-end (GE) signals flanking the viral genes facilitates a tightly regulated transcription cascade. Such regulation is essential in maintaining the balance between viral protein synthesis and genome replication, thereby influencing the virus’s adaptive potential in various host environments.

Phylogenetic analyses based on amino acid sequence alignments have positioned APMV-7 in a clade that shares closer evolutionary relationships with APMV serotypes 2, 6, and 8 rather than with APMV-1 or the serotypes known for causing more prominent clinical disease in poultry. This observation indicates that while all avulaviruses share a common backbone, the divergence seen in APMV-7 reflects distinct evolutionary pressures and host adaptations that may have been shaped by ecological niches, host immune responses, and interspecies transmission dynamics. The genomic features observed, such as the conservation of structural proteins as well as the maintenance of the “rule of six,” suggest that APMV-7’s evolution has been guided by a need to maintain critical functional domains while still allowing for enough flexibility to adapt to diverse avian hosts [1].

Adaptive Strategies and Mechanisms Underpinning Genetic Diversity

APMV-7 demonstrates several adaptive mechanisms that contribute to its persistence in nature despite its apparently restricted host range. One key adaptive strategy is the modulation of the fusion (F) protein. The F protein of APMV-7 contains a cleavage site characterized by a single basic amino acid (101TLPSSR↓F107), a feature typically associated with low virulence in chickens. The molecular configuration at this cleavage site dictates the activation of the fusion machinery necessary for virus entry and cell-to-cell spread. Although the presence of multiple basic residues in other paramyxoviruses often correlates with the potential for systemic infection, APMV-7’s streamlined cleavage site implies an evolutionary balance between efficient host cell entry and the avoidance of excessive pathogenicity that might limit transmission by rapidly incapacitating the host [1]. This balance is a critical component of avian paramyxovirus evolution, as excessive virulence often results in an evolutionary dead-end by drastically reducing host survival.

Another adaptive mechanism residing within the P gene of APMV-7 involves the phenomenon of RNA editing. The P gene in paramyxoviruses is known to harbor a conserved editing site (in APMV-7, characterized by a specific U-rich motif), which facilitates the generation of accessory proteins such as V and W. These proteins are integral to subverting host immune responses, particularly by interfering with interferon signaling pathways. By creating protein variants through RNA editing, APMV-7 is able to fine-tune its interaction with the host’s innate immune defense, enhancing viral survival in the face of host antiviral mechanisms. This molecular strategy not only broadens the virus’s protein repertoire but also contributes significantly to the genetic diversity observed among viral populations, offering a means to rapidly adjust to selective pressures in distinct ecological settings [1].

Furthermore, the interplay between the virus’s limited in vitro host range and its genomic composition suggests that APMV-7 may be characterized by a refined adaptation to specific avian hosts. The observation that the virus achieves efficient replication without the need for exogenous proteases in cell culture underscores a potential adaptation mechanism in which APMV-7 may rely on host-specific proteolytic enzymes present in the primary target tissues of its natural host. Such adaptations can be advantageous in natural ecosystems, where the availability of host enzymes is variable, and they highlight the evolutionary pressures that mold virus–host interactions.

Epidemiological Context and Broader Implications

The evolutionary patterns observed in APMV-7 are not solely of academic interest but also hold implications for avian health and the poultry industry. While APMV-7 is categorized as avirulent in chickens based on its molecular characteristics and in vivo replication profiles, its evolutionary proximity to other serotypes that possess problematic pathogenic potential in both wild and domestic birds raises the importance of continued surveillance. International organizations such as the World Organisation for Animal Health (WOAH), the Centers for Disease Control and Prevention (CDC), and the Food and Agriculture Organization (FAO) emphasize the importance of monitoring avian viruses that share genomic traits with economically significant pathogens. In this context, understanding the adaptive mechanisms and genetic diversity of APMV-7 is crucial for early detection of any evolutionary shifts that might alter its host range or virulence profiles.

Moreover, APMV-7's ability to maintain a relatively conserved genomic backbone while employing nuanced adaptive strategies such as RNA editing and strategic modulation of its fusion protein underscores the complex balance these viruses must achieve to persist in nature. Such balances ensure that the virus remains sufficiently benign to facilitate transmission through its natural reservoir, yet retains the capacity for adaptation should ecological or immunological pressures necessitate a shift in pathogenic behavior. In light of the global reach and significant impact of avian pathogens, the detailed study of APMV-7’s evolution represents a microcosm of viral adaptive evolution that can inform broader surveillance and vaccine development efforts across diverse paramyxovirus serotypes [1].

By drawing comparisons with other avulaviruses whose genomic and adaptive characteristics have been well documented, it becomes evident that the evolutionary narratives of these viruses are shaped by a combination of genetic conservation and strategic variability. The genetic robustness of APMV-7, as evidenced by its conserved transcriptional signals, editing mechanisms, and fusion protein architecture, provides it with a stable platform upon which adaptive mutations can arise. This evolutionary strategy not only assists in evading host immunological barriers but also ensures long-term persistence within avian populations across different geographical regions and ecological niches.

References

[1] Xiao S, Paldurai A, Nayak B, Subbiah M, Collins P, Samal S. Complete genome sequence of avian paramyxovirus type 7 (strain Tennessee) and comparison with other paramyxoviruses. Virus Research. 2009. DOI: https://doi.org/10.1016/j.virusres.2009.06.003

[2] Gogoi P, Ganar K, Kumar S. Avian Paramyxovirus: A Brief Review. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12355

[3] Yin R, Zhang P, Liu X, Chen Y, Tao Z, Ai L, et al.. Dispersal and Transmission of Avian Paramyxovirus Serotype 4 among Wild Birds and Domestic Poultry. Frontiers in Cellular and Infection Microbiology. 2017. DOI: https://doi.org/10.3389/fcimb.2017.00212

[4] Ramey A, Goraichuk I, Hicks J, Dimitrov K, Poulson R, Stallknecht D, et al.. Assessment of contemporary genetic diversity and inter-taxa/inter-region exchange of avian paramyxovirus serotype 1 in wild birds sampled in North America. Virology Journal. 2017. DOI: https://doi.org/10.1186/s12985-017-0714-8

[5] Xiao S, Subbiah M, Kumar S, Nardi RD, Terregino C, Collins P, et al.. Complete genome sequences of avian paramyxovirus serotype 6 prototype strain Hong Kong and a recent novel strain from Italy: evidence for the existence of subgroups within the serotype. Virus Research. 2010. DOI: https://doi.org/10.1016/j.virusres.2010.02.015

[6] Paldurai A, Subbiah M, Kumar S, Collins P, Samal S. Complete genome sequences of avian paramyxovirus type 8 strains goose/Delaware/1053/76 and pintail/Wakuya/20/78. Virus Research. 2009. DOI: https://doi.org/10.1016/j.virusres.2009.02.003

[7] Reeves AB, Poulson R, Muzyka D, Ogawa H, Imai K, Bui VN, et al.. Limited evidence of intercontinental dispersal of avian paramyxovirus serotype 4 by migratory birds. Infection, Genetics and Evolution. 2016. DOI: https://doi.org/10.1016/j.meegid.2016.02.031

[8] Khattar S, Nayak B, Kim S, Xiao S, Samal S, Paldurai A, et al.. Evaluation of the Replication, Pathogenicity, and Immunogenicity of Avian Paramyxovirus (APMV) Serotypes 2, 3, 4, 5, 7, and 9 in Rhesus Macaques. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0075456

[9] Satharasinghe D, Murulitharan K, Tan SW, Yeap S, Munir M, Ideris A, et al.. Detection of Inter-Lineage Natural Recombination in Avian Paramyxovirus Serotype 1 Using Simplified Deep Sequencing Platform. Frontiers in Microbiology. 2016. DOI: https://doi.org/10.3389/fmicb.2016.01907

[10] Chong Y, Padhi A, Hudson P, Poss M. The Effect of Vaccination on the Evolution and Population Dynamics of Avian Paramyxovirus-1. PLoS Pathogens. 2010. DOI: https://doi.org/10.1371/journal.ppat.1000872

[11] Bykov Y, Javaheri A, Mena I, García‐Sastre A, Cuadrado-Castano S. Avian paramyxovirus 4 has potent antitumor activity that surpasses the oncolytic effect of NDV in colon carcinoma and melanoma in vivo models. Journal of Immunology. 2023. DOI: https://doi.org/10.4049/jimmunol.210.supp.245.20

[12] Hicks J, Dimitrov K, Afonso C, Ramey A, Bahl J. Global phylodynamic analysis of avian paramyxovirus-1 provides evidence of inter-host transmission and intercontinental spatial diffusion. BMC Evolutionary Biology. 2019. DOI: https://doi.org/10.1186/s12862-019-1431-2

[13] Hines N, Miller CL. Avian Paramyxovirus Serotype-1: A Review of Disease Distribution, Clinical Symptoms, and Laboratory Diagnostics. Veterinary Medicine International. 2012. DOI: https://doi.org/10.1155/2012/708216

[14] Mase M, Kanehira K. Simple differentiation of avirulent and virulent strains of avian paramyxovirus serotype-1 (Newcastle disease virus) by PCR and restriction endonuclease analysis in Japan.. Journal of Veterinary Medical Science. 2012. DOI: https://doi.org/10.1292/JVMS.12-0178

[15] Zhao N, Grund C, Beer M, Harder T. Engineered recombinant protein products of the avian paramyxovirus type-1 nucleocapsid and phosphoprotein genes for serological diagnosis. Virology Journal. 2018. DOI: https://doi.org/10.1186/s12985-018-0924-8

[16] Espejo R, Goraichuk I, Suarez DL, Breedlove C, Toro H. Avian Paramyxovirus Type 1 from Wild Birds: Population Adaptation and Immunogenicity in Chickens.. Avian diseases. 2025. DOI: https://doi.org/10.1637/aviandiseases-d-25-00026

[17] Ross CS, Mahmood S, Skinner P, Mayers J, Reid S, Hansen RDE, et al.. JMM Profile: Avian paramyxovirus type-1 and Newcastle disease: a highly infectious vaccine-preventable viral disease of poultry with low zoonotic potential.. Journal of Medical Microbiology. 2022. DOI: https://doi.org/10.1099/jmm.0.001489

[18] Samuel AS, Subbiah M, Shive H, Collins P, Samal S. Experimental infection of hamsters with avian paramyxovirus serotypes 1 to 9. Veterinary Research. 2011. DOI: https://doi.org/10.1186/1297-9716-42-38

[19] Khattar S, Kumar S, Xiao S, Collins P, Samal S. Experimental Infection of Mice with Avian Paramyxovirus Serotypes 1 to 9. PLoS ONE. 2011. DOI: https://doi.org/10.1371/journal.pone.0016776

[20] Elbehairy MA, Khattar S, Samal S. Recovery of Recombinant Avian Paramyxovirus Type-3 Strain Wisconsin by Reverse Genetics and Its Evaluation as a Vaccine Vector for Chickens. Viruses. 2021. DOI: https://doi.org/10.3390/v13020316

[21] Yoshida A, Samal S. Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene. Frontiers in Microbiology. 2017. DOI: https://doi.org/10.3389/fmicb.2017.00693

[22] Musako C, Abolnik C. Determination of the seroprevalence of Newcastle disease virus (avian paramyxovirus type 1) in Zambian backyard chicken flocks.. Onderstepoort Journal of Veterinary Research. 2012. DOI: https://doi.org/10.4102/ojvr.v79i1.502

[23] Tolf C, Wille M, Haidar A, Avril A, Zohari S, Waldenström J. Prevalence of avian paramyxovirus type 1 in Mallards during autumn migration in the western Baltic Sea region. Virology Journal. 2013. DOI: https://doi.org/10.1186/1743-422X-10-285

[24] Shirvani E, Varghese BP, Paldurai A, Samal S. A recombinant avian paramyxovirus serotype 3 expressing the hemagglutinin protein protects chickens against H5N1 highly pathogenic avian influenza virus challenge. Scientific Reports. 2020. DOI: https://doi.org/10.1038/s41598-020-59124-x

[25] Yoshida A, Kim S, Manoharan VK, Varghese BP, Paldurai A, Samal S. Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-42004-4 *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.